{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0002022416","name":"Silexion Therapeutics Corp","summary":"Silexion Therapeutics Corp is a clinical-stage oncology biotechnology company developing siRNA-based treatments targeting mutated KRAS oncogenes in cancers such as pancreatic, colorectal, and lung cancer. Its lead product, SIL204, is a second-generation siRNA designed to silence mutated KRAS protein production in locally advanced pancreatic cancer (LAPC) patients. The company uses an Integrated Treatment Regimen combining intratumoral and subcutaneous administration with standard-of-care chemotherapy, building on prior Phase 1 and 2 clinical experience with its first-generation siG12D-LODER product.","people":[],"products":[{"name":"SIL204","type":"platform","description":"Second-generation siRNA candidate targeting KRAS G12D/V mutations in LAPC, administered intratumorally and subcutaneously in combination with standard-of-care chemotherapy."},{"name":"siG12D-LODER (Loder)","type":"platform","description":"First-generation siRNA formulated in biodegradable PLGA matrix for extended intratumoral release targeting KRAS G12D mutation in LAPC patients."}],"partnerships":[{"partner_name":"Federal Institute for Drugs and Medical Devices (BfArM)","partnership_type":"development","description":"BfArM agreed in principle to the design of the planned Phase 2/3 trial; Silexion plans to submit a clinical trial application in Germany in Q1 2026.","start_date":null},{"partner_name":"Israeli Ministry of Health","partnership_type":"development","description":"Silexion submitted an application in Q4 2025 to commence the adaptive Phase 2/3 trial with a safety run-in at several locations in Israel.","start_date":null}],"affiliations":[],"origin":{"leaf":"eaa0dda5b02eb710f1bd8ca2e4d72d40082b349bd43c6282aca327c80ec9348f","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ac1fc073c5fffe2f53b54efed592b2cfd824d98f5697172233937a8804eaa2d3","parent":"0fef79be94871649a54c2f62a70ab0686fb68630b29608de0c55928e568bd3ba","source":"0001178913-26-000953","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":7,"hourly_limit":500,"remaining":493,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}